Journal article
Tifacogin (Chiron Corp/Pharmacia Corp).
Abstract
Tifacogin is a recombinant tissue factor pathway inhibitor (rTFPI) under development by Pharmacia Corp (formerly GD Searle) and Chiron as a potential treatment for sepsis. The product is in phase III trials [406208]. In July 2000, Pharmacia anticipated regulatory filings in 2002 [374505]. Chiron and Searle conducted research on TFPI independently in the early 1990s and entered an agreement to collaborate on the development, manufacturing and …
Authors
Sne N; Ondiveeran HK; Fox-Robichaud A
Journal
IDrugs, Vol. 5, No. 1, pp. 91–97
Publication Date
January 2002
ISSN
1369-7056